Medullary Thyroid Cancer

Medullary Thyroid Cancer

Postby PharmD » Thu Dec 02, 2010 5:14 pm

Preliminary results from an open-label phase II study of sorafenib in patients with metastatic medullary thyroid cancer (MTC) showed a partial response in one patient with sporadic MTC and a median progression-free survival of nearly 18 months.
Lam, ET, Ringel, MD, Kloos, RT, et al. Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer. J Clin Oncol 2010; 28:2323.
User avatar
PharmD
Site Admin
 
Posts: 165
Joined: Tue Nov 23, 2010 12:29 am

Return to THYROID

Who is online

Users browsing this forum: No registered users and 1 guest

cron